Ranitidin
RANITIDINE BASE · Ranitidin · Trigger · RANITIDINE USP · RND · U1cex · Taural · Zantae
Identifikatoren & physikalische Daten
| CAS No. | 66357-35-5 |
|---|---|
| Summenformel | C13H22N4O3S |
| Durchschnittliche Molmasse | 314,41 g/mol |
| Monoisotopische Masse | 314,14126156 g/mol |
| SMILES | CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1 |
| InChIKey | VMXUWOKSQNHOCA-UHFFFAOYSA-N |
| PubChem CID | 5039 |
| DTXSID | DTXSID8045191 |
| Lokaler Name | Ranitidin |
Chemische & physikalische Eigenschaften
| XLogP | 0,3 |
|---|---|
| Polarare Oberfläche (TPSA) | 112 |
| H-Brücken-Donoren | 2 |
| H-Brücken-Akzeptoren | 7 |
| Frei drehbare Bindungen | 9 |
| Schwere Atome | 21 |
| Formalladung | 0 |
| Komplexität | 347 |
| Arzneimittel | Pharmaceuticals -> Antiulcer Drugs |
| Collision Cross Section | 169.0 Ų [M+H]+ [CCS Type: DTBuffer gas: N2Ionization: ESI+Dataset: TOXCASTSource Identifier: DTXSID8045191] |
| Schmelzpunkt | 69-70°C |
| Siedepunkt | 437.1±45.0 °C(Predicted) |
| Dichte | 1.184±0.06 g/cm3(Predicted) |
| Lagerbedingungen | Desiccate at +4°C |
| Löslichkeit | H2O: 1.8 mg/mL24.7 mg/mL |
| pKa (Säurekonstante) | pKa 2.19±0.04 (Uncertain) |
| Aggregatzustand | solid |
| Farbe | tan |
| Stabilität | Hygroscopic |
| CAS Datenbank | 66357-35-5(CAS DataBase Reference) |
| NIST chemische Informationen | Ranitidine(66357-35-5) |
| EPA chemische Informationen | 1,1-Ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro- (66357-35-5) |
Sicherheit & Vorschriften
| Wassergefährdungsklasse (WGK) | 2 |
|---|---|
| RTECS-Nr. | KM6557000 |
| Toxizität | LD50 oral in rat: > 5gm/kg |
| Sicherheitshinweise (S) | 22-24/25 |
| Gefahrstoffdaten | 66357-35-5(Hazardous Substances Data) |
Anwendungen & Verwendung
Beschreibung
Ranitidine, a H2-receptor agonist, caused contact dermatitis within the pharmaceutical industry.
History
Ranitidine was first prepared in England as AH19065 by John Bradshaw in the summer of 1977 in the Ware research laboratories of Allen and Hanburys, part of the former Glaxo organisation.Glaxo refined the model further, by replacing the imidazole ring of cimetidine with a furan ring with a nitrogen-containing substituent, and in doing so developed ranitidine. Ranitidine was found to have a far-improved tolerability profile (i.e. fewer adverse drug reactions), longer-lasting action, and 10 times the activity of cimetidine. Ranitidine was introduced in 1981, and was the world's biggest-selling prescription drug by 1987. Subsequently, it was largely superseded by the more effective proton-pump inhibitor (PPI) class of drugs, with omeprazole becoming the biggest-selling drug for many years.In September 2019, the probable carcinogen N-nitrosodimethylamine (NDMA) was discovered in ranitidine products from a number of manufacturers, resulting in recalls; in April 2020, it was withdrawn from the United States market and suspended in Europe and Australia. In 2024, ranitidine was re-approved for sale in Australia after the local sponsor of Zantac changed suppliers and tablet formulation. The new formulation was demonstrated to be stable throughout its shelf life and that nitrosamines are controlled within internationally established acceptable intake limits applied to the maximum daily dose.
Verwenden
Ranitidine (cas# 66357-35-5) was used as a standard for testing the therapeutic effect of brown propolis extract against aspirin and ethanol- induced gastric ulcers.